bluuebunny/crossref_metadata_2025 huggingface dataset:
P180 A STRANGE JET IN A PATIENT WITH A MECHANICAL AORTIC VALVE
Authors: Gizzi G , D‘Agostino S , Parato V
Published: May 2022

Clinical Case

A 68–year–old male patient with a history of ischemic heart disease in three vessel coronary artery disease who underwent surgical myocardial revascularization in 2012 by CABG (LIMA to LAD); previous aortic valve replacement with mechanical prosthesis (2012); previous PMK implant in permanent AF. The patient arrived at our observation transferred from another hospital where, due to heart failure with new–onset severe left ventricular dysfunction, he had undergone a coronary examination with evidence of occlusion of LAD in the middle tract, patency of LIMA to LAD, severe LM/LCx stenosis followed by IVUS guided PTCA–DES stenting with final TIMI 3. During his hospitalization in our care unit he repeated trans–thoracic echocardiogram examination which documented: severe left ventricular dilatation with reduced EF (40%), left atriomegaly, bileaflet mechanical aortic prosthesis in place with normal systolic opening, normal trans–prosthetic gradients, absent peri or intraprosthetic regurgitation jet, moderate mitral valve regurgitation with central jet, right–sided sections of normal size and contractility in the absence of signs of increased pulmonary pressures. Color Doppler also documented a high–speed jet starting from the prosthesis–LAM interface directed towards the left atrium of unclear interpretation. To better interpretate this finding a transesophageal echocardiogram was performed which confirmed the correct functioning of the aortic mechanical prosthesis, absence of periprosthetic leaks and confirmed a high–speed jet directed from the prosthesis–LAM interface towards the left atrium compatible with perforation of the mitro–aortic continuity tissue. The patient was therefore sent for cardiac surgery and is currently awaiting reoperation.
P192 LONG TERM PROGNOSTIC EFFECT OF LIPROTEIN(A) IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS AFTER MYOCARDIAL INFARCTION
Authors: Cancro F , Baldi C , Silverio A , Di Maio M , Esposito L , Tedeschi M , Cristiano M , Sabatino M , Romei S , Vecchione C , Galasso G
Published: May 2022

Aims

To describe the baseline clinical, laboratory and angiographic characteristics of patients with acute myocardial infarction (MI) according to the presence or not of diabetes mellitus (DM), and to evaluate if DM may influence the effect of lipoprotein(a) [Lp(a)] serum level on long–term outcome in this very high–risk population.

Methods

This was a retrospective, single–center, study including consecutive patients admitted with MI diagnosis between January 1, 2017, and December 31, 2020. The availability of data on baseline Lp(a) serum level was considered as an inclusion criterion. The study population was divided into two groups according to the presence or not of DM. The Lp(a) value of 50 mg/dL was used to test the hypothesis of a different effect of Lp(a) on the clinical outcome of patients with or without DM. The primary study outcome was all–cause death at 3–year follow–up.

Results

The study population included 997 patients (mean age 63.7±13.5 years; 75.7% were males). Diabetes was reported in 280 (28.1%) patients. DM patients were older than those without DM (67.8±12.1 vs. 62.0±13.7 years, p < 0.001) and showed a significantly higher prevalence of dyslipidemia, hypertension, obesity, prior MI and prior coronary revascularization (p < 0.001). DM patients showed higher SYNTAX score value (19.8 vs. 15.1, p < 0.001) and a higher prevalence of left main involvement (6.3 vs. 3.1, p = 0.023). At Kaplan–Meier analysis, in the group without DM, patients with Lp(a)≥50 mg/dL showed a significantly lower long–term survival compared with those with Lp(a)<50 mg/dL (Log–Rank=0.004). In DM patients DM, conversely, no survival difference was found between patients with Lp(a)≥50 mg/dL vs. those with Lp(a)<50 mg/dL. At multivariable Cox regression analysis, in patients without DM, Lp(a) serum level (HR: 2.68, 95% CI 1.23–5.83; p = 0.013) and age (HR: 1.06, 95% CI 1.04–1.09; p < 0.001) were independent predictors of mortality at 3–year follow–up. Among DM patients, only age was independently associated with 3–year mortality (HR: 1.07, 95% CI 1.03–1.10; p < 0.001) (Table).

Conclusion

In this MI population, Lp(a) was independently associated with long–term mortality in patients without DM, but not in patients with DM. Whether DM can modify the effect of Lp(a) on clinical outcome after MI requires confirmation by larger prospective studies.
P194 AN UNUSUAL PRESENTATION OF ST–SEGMENT ELEVATION MYOCARDIAL INFARCTION: LEFT VENTRICULAR THROMBOSIS AND ISCHEMIC STROKE
Authors: Santus S , Utzeri E , Sanna N
Published: May 2022

Background

Patients with large anterior MI associated with a reduced systolic function are at increased risk for developing left ventricular thrombosis. Stasis of blood in the ventricular cavity and the inflammation associated with ischemic injury are the causes of left ventricular thrombosis and increased risk of stroke. It usually develops within the first week and often the first day after infarction. Embolization takes place during the first 1 to 3 months. Our patient presented a very early embolization.

Case Report

A 70–year–old smoker man, without other cardiovascular risk factors, presented at the emergency department of our hospital with acute aphasia and right facio–brachio–crural hemiparesis. The 12–lead ECG revealed ST–elevation in V2–V5 and Q waves in V1–V3. Patient was asymptomatic for angina at the time of presentation and the days before. He performed an urgent head–CT that revealed proximal occlusion of the M2 tract of left middle cerebral artery cause of ischemic stroke (NIHSS 13). Then, he underwent per–cutaneous mechanical thrombectomy with complete re–canalization of the vessel. Immediately after he performed coronary angiography that showed the occlusion of anterior inter–ventricular artery treated by angioplasty and implant of drug eluting stent. Both procedures have been well tolerated by the patient without complications. Measurements of high–sensitivity cardiac Troponin demonstrated a peak and following fall of the values. A two–dimensional echo–cardiogram showed akinesia of anterior wall and apical segments of LV with EF < 40% and ventricular thrombus. A multidisciplinary team evaluated evolution of cerebral ischemic lesion and patient’s clinical conditions and established the correct time and management of therapy with DAPT (aspirin+clopidogrel) and VKA. It has been prescribed three months DAPT+VKA therapy and later DAT (aspirin+VKA) for one year. Patient has been discharged with minor aphasia, without cardiac symptoms and good hemodynamic status.

Conclusion

Left ventricular thrombosis is a frequent complication of anterior MI. The optimal frequency of follow–up imaging and time of treatment are not known. Our patient had a very early presentation. It should be useful to have guidelines to prevent and treat left ventricular thrombosis. Despite common use of anticoagulant drugs in the treatment of left ventricular thrombosis, there aren‘t randomized clinical trials evaluating the safety and efficacy of this strategy.
P197 TAKO TSUBO SYNDROME IN MAN FOR ‘SMART WORKING’ COMPLICATED BY ACUTE HEART FAILURE AND SAM. PRESENCE OF MYOCARDIAL BRIDGE OF IVA ‘INNOCENT BYSTANDER’ OF THE CLINICAL PICTURE
Authors: Occhiuzzi E , Ranfone F , Ippoliti C , Valentini G , Balsano C
Published: May 2022

Male, 59 years old with no significant pathological history or cardiovascular risk factors. Access to the ER ( 12.30 AM ) with infero–lateral STEMI (Killip I, 2 hours of symptom onset; haemodynamic and electrical stability): chest pain associated with profuse sweating and transient arterial hypotension, ST elevation in V3–V6 and inferior leads on the ECG and apical hypokinesia with slight reduction of LVEF (50%) on the Trans–Thoracic Echocardiography. Urgent coronary angiography: non–obstructive coronary arteries stenosis, short intramyocardial tract of DA with moderate systolic compression with ‘milking effect‘. Blood sampling: mild elevation of cardiac troponin hs value (479 pg / ml), mild anemia and thrombocytopenia; normal value of markes of liver and kidney function. Hospitalization in Cardiac ICU with standard antithrombotic and anti–ischemic therapy. 12 hours after admission (01.00 PM) acute low–flow heart failure with pulmonary edema treated with inotropic agent and need of endotracheal intubation and ventilatory support (ineffective attempt of NIV); ECG unchanged from the previous one and appearance of LVEF 25% for akinesia of septum, apex and lateral wall. Peak of troponin 2083 pg / ml III day: effective extubation with successive cycles of NIV and weaning from noradrenaline. Progressive recovery of LVEF with appearance of SAM with LVOT dynamic obstruction (v max> 4m / s at pulsed doppler) and moderate mitral regurgitation: stop inotropic agent and start beta–blocker therapy (atenolol) not tolerated for hypokinetic arrhythmias (also total BAV) and then successful replaced in the following days with low doses of bisoprolol. Post–Iintubation pneumonia treated with antibiotic therapy. X day: hemodynamic and electrical stability, disappearance of the SAM with complete recovery of the left ventricle contractile function, mild mitral regurgitation(minimal valve prolapse) Cardiac MRI: normal LVEF, absence of myocardial LGE with the exception of small areas of the papillary muscles due to traction of the mitral flaps. In the patient‘s medical history: stressful last months related to smart working and family problems; absence of a specific identifiable trigger.

Conclusions

Stress cardiomyopathy in man patient complicated by progressive acute heart failure and SAM with rapid restitutio ad integrum. Presence of DA myocardial bridge with absence of myocardial LGE on MRI.
P199 PROCALCITONIN PREDICTS BACTERIAL INFECTION, BUT NOT LONG–TERM OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Fabbri G , Pavasini R , Marchini F , Bianchi N , Campo G , Guardigli G
Published: May 2022

Background

Procalcitonin (PCT) is an acute phase protein which plasma levels raise also in sterile inflammation. For this reason, its role in the acute coronary syndrome (ACS) setting would be twofold: as a marker of infection and also as a prognosticator of generic inflammation. High PCT values have been related to worse prognosis in patients with cardiogenic shock. If PCT values may predict the risk of bacterial infections and long–term outcome in patients with acute coronary syndromes has been less investigated.

Methods

Consecutive patients with a diagnosis of ACS with PCT level assessed during the first 24 hours of hospitalization were enrolled. The primary outcome was the occurrence of bacterial infection defined by the occurrence of fever and of at least one positive blood or urinary culture with clinical signs of infection. The secondary outcome was the 1–year occurrence of the composite outcome all–cause mortality, stroke and myocardial infarction.

Results

Overall 569 patients have been enrolled (mean age 69.37±14 years, 30% females): 44 (8%) of them met criteria for bacterial infection. Age, female sex, smoking habit, heart rate, systolic blood pressure (SBP), heart failure after admission, coronary angiography, hemoglobin, creatinine clearance and PCT above the cut–off value were predictors of the outcome. After multivariate analysis, PCT and SBP resulted as independent predictors of bacterial infections (OR for PCT above the cut–off 2.67, 95%CI 1.09–6.53, p = 0.032; OR for SBP 0.98, 95%CI 0.97–0.99, p = 0.043). At 1–year, the composite outcome of all–cause death, MI and stroke occurred in 104 patients (18%). PCT did not result as an independent predictor of the composite outcome.

Conclusions

In patients with ACS PCT levels at hospital admission are predictor of bacterial infection but not of the composite lomg–term outcome of all–cause mortality, stroke and myocardial infarction.
P200 ISCHEMIC HEART IN PAZIENTS UNDER 30: AN UNSOLVED CHELLENGE
Authors: Annalisa F , Trotta R , Pollicino T , Abbracciavento L , Luzzi G
Published: May 2022

Background

The pathogenesis of ischemic heart disease (IHD) in young patients is still unclear. Several studies have demonstrated the existence of peculiar cardiovascular risk factors (CRFs) that differ from the typical factors involved in the more common IHD of adults.Plaque rupture represents the most common etiology of myocardial infarction (MI), nonetheless, other events can play a role in young patients affected by IHD, including coronary artery plaque erosion, coronary microvascular dysfunction, spontaneous dissection of the coronary artery, and coronary artery spasm secondary to drug abuse. Due to the differences in the clinical manifestations, diagnosis, and therapeutic management, further research is needed to study the profile of MI in young patients1

Clinical Case

A 28–year–old male, occasional smoker, negative familiar anamnesis for IHD. His past medical history was significant for an acute coronary syndrome (ACS) STEMI at the age of 20 years old, treated with percutaneous transluminal coronary angioplasty (PTCA) with scaffold in the interventricular anterior artery (IVA). After 7 years he was admitted following a thrombotic occlusion of the IVA, managed with PTCA/ drug–eluting stent (DES) followed by coronary artery bypass surgery diverting the blood flow of the IVA in the left internal mammary artery (IMA). After only 11 months he presented with a new ACS NSTEMI treated with PTCA/DES of the IVA in the left IMA. No biochemical signs of coagulopathy or peripheral artery disease were disclosed, and the supra–aortic trunks resulted normal. Nevertheless, a significant increase in the blood levels of homocysteine and slightly elevated values of fibrinogen, D–dimers, and C–reactive protein. Erythrocyte sedimentation rate resulted within the physiological ranges.

Discussion and Conclusion

The peculiar medical history of the described patient suggests a marked tendency not only for the formation and plaque rupture but also for platelet aggregation. The only significant and persistent values that were found to be elevated were homocysteine and inflammatory markers. One–year follow–up examination revealed complete regression of the symptoms with double antiaggregating therapy and supplements of folic acid. The rarity of such cases should prompt new research to better understand IHD in this population and possible targeted treatments Acute Myocardial Infarction in Young Individuals; Rajiv Gulati; Mayo Clinic Proceedings, V 95, I. 1, P136–156, 2020.
P202 PRETREATMENT WITH ANTAGONISTS OF P2Y12 PLATELETS RECEPTORS IN ST–ELEVATION MYOCARDIAL INFARCTION: CLINICAL AND ANGIOGRAPHIC OUTCOMES
Authors: Antonucci A , Cutolo A , Gallo F , Bellin A , Cavalli G , Barbierato M , Themistoclakis S
Published: May 2022

Background

The use of antagonists of P2Y12 platelets receptors as antiplatelets drugs is a cornerstone in the treatment of ACS. Many efforts are made to understand the right timing of beginning this therapy with the purpose to reduce intra– and periprocedural complications (stent thrombosis, no reflow phenomenon). The rationale behind “pretreatment” (administration of antagonists of P2Y2 platelet receptor before the coronarography) is valuable but the evidences are lacking, also in the setting of ACS–STEMI.

Method and Objectives

We conduct an observational, monocentric (Ospedale dell’Angelo – Venezia Mestre), retrospective study including patients with STEMI (1st January 2016 – 9th august 2018). We compared two strategies of administration of clopidogrel, ticagrelor and prasugrel (pretreatment vs no pretreatment). Primary endpoints were bleeding BARC 3–5, acute or subacute stent thrombosis and TIMI flow grade > 0 in the culprit coronary. Secondary endpoints were cardiovascular and no cardiovascular in–hospital mortality and in–hospital neurological complications.

Results

We studied 501 patients (199 in the group pretreated and 302 in the group no pretreated). The median time from first medical contact to PCI was 70,5 minutes in the pretreated group and 60 minutes in the no pretreated group (p = 0.022). No significant differences between the two groups were observed in terms of acute or subacute stent thrombosis (OR 3.72 [0.82–14.20], p = 0.09) e TIMI flow grade > 0 in the culprit coronary (OR 1.11 [0.77–1.58], p = 0.58). In the multivariate analysis we observed that bleeding BARC 3–5 significantly were increased in the pretreated group (adjusted OR 2.78 [1.13–6.83, p = 0.025). In the subgroup analysis, the pretreated subjects with age > 75 were at augmented risk of bleeding BARC 3–5.

Conclusions

Pretreatment in the setting of ACS–STEMI is not associated with benefits in terms of acute or subacute stent thrombosis and perfusion of culprit coronary but may cause clinically relevant bleedings, in particular in the elderly (age > 75).
P204 FRACTIONAL EXCRETION OF ALBUMIN DURING ACS AS A PREDICTOR OF THE VERY LONG–TERM MORTALITY AND CAUSES OF DEATH. RESULTS FROM 22 YEARS OF FOLLOW–UP OF THE ABC STUDY ON HEART DISEASE
Authors: Mahmoud H , Berton G , Cordiano R , Palmieri R , Cavuto F , Mahmoud M , Sitta N , Merotto D , Preti G , Segafedo B
Published: May 2022

Introduction

Several clinical risk predictors have been used to stratify risk in acute coronary syndromes (ACS) patients. Yet, few have been tested or demonstrated usefulness in the very long–term follow–up.

Purpose

To investigate the association between baseline albumin fractional excretion (AlbFE) and the long–term mortality and causes of death after ACS.

Methods

This prospective analysis included 579 patients admitted with ACS to 3 hospitals and discharged alive. Clinical and laboratory data were gathered within the first 7 days of hospitalization. Baseline AlbFE calculated as ((Serum Cr*Urine Alb) / (Serum Alb*UCr)) %, Patients were followed–up for 22 years.

Results

All except three patients completed the follow–up, and by its end 449(78%) patients were dead. Causes of death were sudden cardiac death (SCD) in 85(15%), non–sudden cardiac death (non–SCD) in 176(30%), non–cardiac death (non–CD) in 166 (29%). Baseline AlbFE median (IQR) values were: 4.1% (1.5–12.4), 1.7% (0.8–5.3), 1.3% (0.6–3.5) at 1st,3rd, and 7th hospitalization, respectively. At cox regression analysis, 3rd day AlbFE was associated to all–cause mortality: (HR = 1.4, 95%CI=1.3–1.5; p < 0.0001). It was also associated to the risk of non–SCD (HR = 1.6, 95%CI=1.4–1.7; p < 0.0001), SCD (HR = 1.3, 95%CI=1.2–1.5; p < 0.0001), and to non–CD (HR = 1.3, 95%CI=1.1–1.4; p < 0.0001). Using a cox regression model adjusted for age, gender diabetes and baseline left ventricular ejection fraction: the 3rd day AlbFE was associated to all–cause mortality (HR = 1.1, 95%CI=1.1–1.2; p < 0.0001), and to non–SCD risk (HR = 1.2, 95%CI=1.1–1.4; p < 0.0001) but not to the risk of SCD or non–CD (HR = 1.1, 95%CI=0.9–1.2; p = 0.45), and (HR = 1.1, 95% CI=1.0–1.2; p = 0.06), respectively. Same results were obtained with 1st an 7th day AlbFE values. Of relevance, a sub–analysis showed that the association between the 3rd day AlbFE and all–cause mortality kept true both in the 1st (1–11 years) and the 2nd (12–22 years) half of follow up period; (HR = 1.5, 95%CI=1.4–1.6; p < 0.0001) and (HR = 1.2, 95%CI=1.1–1.4; p = 0.001) in the unadjusted model and (HR = 1.3, 95%CI=1.2–1.4; p < 0.0001) and (HR = 1.1, 95%CI=1.0–1.3; p = 0.02) in age and gender–adjusted model for the 1st and the second half respectively.

Conclusion

The present results showed that baseline AlbFE is an independent predictor of mortality up to 22 years after ACS, chiefly for non–SCD.
P209 THE FOLLOW–UP OF PATIENTS AFTER ACUTE CORONARY SYNDROME: THE APULIAN PONTE–ACS PROJECT
Authors: Scicchitano P , Locuratolo N , Lillo A , Sublimi Saponetti L , Palumbo V , Lanzone S , Campanella C , Mancini L , Massari F , Landriscina R , Barba G , De Santis A , Caldarola P
Published: May 2022

Background

Patients discharged after acute coronary syndrome (ACS) deserve a tight follow–up in order to optimize long–term pharmacological treatments and prevent the occurrence of adverse events. The aim of the PONTE–ACS Project was to evaluate the impact of a dedicated cooperative program between hospital and outpatient structures on the persistance on recommended therapies and long–term outcome occurrence in patients discharged after ACS.

Materials and Methods

This was a prospective, longitudina, cohort study. We enrolled patients who were discharged after ACS and/or after coronary revascularization in the HUB centres of ASL Bari. Patients underwent cardiologic evaluation and laboratory examination at 30 days, 3–, 6–, and 12–months from the index event. The following endpoint were considered: all–cause mortality, ACS recurrence/cardiac ischemia/angina, restenosis/intrastent thrombosis, stroke/transient ischemic attack (TIA), heart failure, any bleeding. Adherence and persistence to therapies were evalauted as well as the percentage of patients who reached the recommended goals.

Results

We enrolled 2476 patients (77.4% male, mean age: 67.2±12.0 yrs). After one–year follow–up, 99.5% (p < 0.05) were on statin–therapy, 16.1% with ezetimibe (p < 0.01) and 9.9% (p < 0.01) with proprotein convertase subtilisin/kexin type 9 inhibitors. The overall mortality at one–year follow–up was 3.1%, while ACS recurrence/cardiac ischemia/angina and restenosis/intrastent thrombosis were 3% e 1.3%, respectively. Any bleeding rate was 2.2%.

Conclusions

The PONTE–ACS Project was able to improve the management of patients after ACS, to manage a structured follow–up protocol for patients discharged after ACS and/or coronary revascularization, thus improving adhesion to recommended therapies and keeping lower the incidence of major cardiovascular and bleeding events.
P210 VENTRICULAR FIBRILLATION IN AN ELDERLY WOMAN WITH APPARENTLY UNREMARKABLE PAST CARDIOLOGICAL HISTORY: AN UNEXPECTED CULPRIT
Authors: Sansonetti A , Armillotta M , Amicone S , Impellizzeri A , Fabrizio M , Angeli F , Bergamaschi L , Stefanizzi A , Magnani I , Rinaldi A , Foà A , Galiè N , Pizzi C
Published: May 2022

An 85–year–old woman experienced cardiac arrest while she was at the supermarket. Cardiopulmonary resuscitation was promptly performed with ROSC after DC shock on ventricular fibrillation and immediate hemodynamic and neurological recovery. The first ECG performed by the rescuers did not show acute ischemic changes and the patient was admitted to the Cardiological Intensive Care Unit. Past medical history revealed only a previous episode of acute pulmonary embolism for which she was on oral anticoagulant therapy for a limited period of time. She had not family history of sudden cardiac death or cardiomyopathies. Before admission she was completely asymptomatic and she never complained of angina pectoris, palpitation or dyspnoea. The echocardiogram at admission showed moderate left atrial enlargement and hypokinesia of left ventricle apex and mid–apical lateral wall with global EF of 50%. Pulmonary and aortic CT angiography showed no pathological findings. In order to rule out an ACS, the patient underwent a coronary angiography which documented the absence of critical coronary stenosis. Finally, a cardiac MRI with gadolinium was performed, revealing the presence of two small areas of transmural LGE affecting inferior basal and lateral mid–apical segments with no edema, consistent with ischaemic myocardial scars. In light of this findings and to rule out paradoxical coronary artery embolism we decided to perform a transcranial echocolordoppler that showed the absence of a patent foramen ovale. Furthermore, continuous ECG monitoring during the hospital stay did not document arrhythmic recurrences. In consideration of the high probability of ischemic heart disease, therapy with antiplatelet agent, beta–blocker, ace–inhibitor and statin was introduced and the patient was discharged after ICD implantation. Three months later, during her first follow–up visit, we documented short episodes of atrial fibrillation at ICD interrogation. This was in line with the hypothesis of a ventricular fibrillation and cardiac arrest in the contest of an ischemic heart disease with myocardial scars probably due to undatale coronary artery embolism. Oral anticoagulant therapy was started in addition to previous therapy.
P213 ROLE OF ANEMIA AND IRON IMPLEMENTATION ON PROGNOSIS AND MANAGEMENT OF ELDERLY STEMI PATIENTS
Authors: Mircoli L , Tonella T , Carugo S
Published: May 2022

Introduction

Elderly patients with S–T elevation myocardial infarction (STEMI) presented a very high risk for both in–hospital and long–term morbility and mortality. Comorbidities plays a key role in prognosis, in particular anemia (pre–existent or acquired) is a more and more emerging clinical element able to influence short– and long–term clinical outcome. Prognostic role of anemia in elderly STEMI patients in not completely clarified.

Purpose

of the present study is to evaluate the role of anemia and its therapy by iron implementation in a very–old population of STEMI patients followed for 1 year after index event.

Methods

we considered all STEMI patients admitted in our Coronary Care Unit from 2020 to 2021 and we selected only people aged > 80 years–old (n = 120). Haemoglobin (Hb, g/dl) values were considered at admission (T0), at hospital discharge (T1) and after 6 month (T2). In hospital and 1 year mortality, treatment by primary PCI, major bleedings (TIMI criteria), need of transfusion, double antiplatelet therapy (DAPT) discontinuation, were considered and compared between groups of patients without and with anemia (A, Hb < 13.5 for men and <12 for women at T1) and without (NA group). Type of iron implementation (sucrosomial or not) and its tolerability were considered only for A group. Data were expressed as means±SD or % values.

Results

18 patients (15%) presented anemia at T0 (women 66%), 4 (22%) of them showed a TIMI major in–hospital bleeding (3, 20%, required blood transfusion) whereas 5 (5%) in non anemic, in–hospital mortality was similar between anemic and non–anemic (18% vs 17%). Sixteen (14%) presented mild anemia at T1 (14%, A group), mean age were similar to NA group (years, 86±4 vs 85±5, A vs NA, ns). In A 4 (25%) died during follow–up vs 11 (13%) in NA group during 1 year follow–up. Treatment with primary PTCA (31% vs 39%, A vs NA, ns) were similar. DAPT discontinuation In A group 16 patiens were discharged with indication to long–term iron implementation therapy, 6 of them with sucrosomial. Incidence of iron discontinuation was 16% (1 pt) for sucrosomial vs 50% (5 pts) for non–sucrosomial.

Conclusions

In elderly STEMI patients, 1) anemia at hospital admission influences in hospital major bleedings and need of blood trasfusions. 2) anemia at hospital discharge seems to affect DAPT discontinuation and long–term mortality. 3) use of sucrosomial iron reduces probability of discontinuation of implementation therapy.
P216 RENAL RESISTANCE INDEX IS INDEPENDENTLY ASSOCIATED WITH THE WORSENING OF RENAL FUNCTION AFTER CORONARY ANGIOGRAPHY
Authors: Goffredo G , Barone R , Di Terlizzi V , Correale M , Casavecchia G , Ieva R , Cuculo A , Brunetti N , Iacoviello M
Published: May 2022

Background

The term Cardiorenal Syndrome (CS) has been recently introduced to indicate the close relationship between cardiovascular and renal diseases, which are able to reciprocally influence the each other progression. In this setting the renal resistance index (RRI) has been demonstrated to be a useful parameter able to detect patients at higher risk of CS. However, there are no data about its role in predicting worsening of renal function (WRF) mediated by the intravascular administration of contrast.

Aim of the Study

To evaluate the role of RRI in predicting WRF after coronary angiography. METHODS We enrolled 115 patients (mean age 64 years, 73% males, 84% hypertensive, 43% diabetic, 30% with acute coronary syndrome, 21% affected by chronic heart failure, CHF, with a mean left ventricular ejection fraction, LVEF, of 51±11) with suspected coronary artery disease, stable angina, or acute coronary syndromes who have been referred for coronary angiography (with or without pre–existing renal impairment). All patients underwent medical examination, electrocardiogram, echocardiographic and chemical evaluation, and renal arterial echo–color Doppler used to calculate RRI. WRF was defined as an increase of creatinine >0.3 mg/dl and of at least 25% from baseline 24–48 hours after coronary angiography.

Results

After coronary angiography, 14 (12%) of the enrolled patients showed WRF. As shown in the Table, at univariate regression analysis baseline RRI was associated with WRF as well as age, peripheral artery disease, CHF, atrial fibrillation, NYHA class, LVEF, mitral regurgitation (MR), central venous pressure (CVP), tricuspid regurgitation (TR), estimated glomerular filtration rate (GFR). In a multivariate forward stepwise regression model, including all univariate predictors, history of CHF, high CVP and RRI were the only parameters significantly associated with WRF.

Conclusion

Our findings demonstrate that in patients undergoing coronary angiography, history of CHF, high CVP and RRI are independent predictors of WRF. RRI, but not GFR, is independently associated with WRF probably because providing additional relevant information about cardiorenal pathophysiological factors reflecting the hemodynamic status and kidney flow reserve.
P217 SACUBITRIL/VALSARTAN IN ADVANCED HEART FAILURE: SAFETY AND EFFECTS ON HAEMODYNAMIC PARAMETERS
Authors: Gentile P , Cantone R , Perna E , Ammirati E , Varrenti M , D‘Angelo L , Verde A , Foti G , Masciocco G , Garascia A , Frigerio M , Cipriani M
Published: May 2022

Aims

The angiotensin–II receptor neprilysin inhibitor (ARNI), sacubitril/valsartan has been shown to be effective in treatment of patients with heart failure (HF), but limited data is available in patients with advanced disease. This retrospective observational study assessed the effects of ARNI treatment in patients with advanced HF.

Methods

We reviewed medical records of all advanced HF patients evaluated at our center for unconventional therapies from September 2016 to January 2019. We studied 44 patients who started ARNI therapy and who had a hemodynamic assessment before beginning ARNI and after 6 ± 2 months. The primary endpoint was variation in pulmonary pressures and filling pressures at 6 months after starting ARNI therapy.

Results

Mean patient age was 51.6±7.4 years; 84% were male. At 6±2 months after starting ARNI, there was significant reduction of systolic pulmonary artery pressure (PAP) (32 mmHg, IQR 27–45 vs 25 mmHg, IQR 22.3–36.5; p < 0.0001) and median PAP (20 mmHg, IQR 15.3–29.8 vs 17 mmHg, IQR 13–24.8; p = 0.046). Five of 22 patients (23%) were deferred from the heart transplant (HTx) list because of improvement, while four were listed de novo. After 23 ± 9 months, 3 patients were treated with a left ventricular assist device (LVAD) implantation, while 6 patients underwent Heart transplantation (one in emergency conditions for refractory ventricular tachycardia).

Conclusions

Sacubitril/valsartan is effective in reducing filling pressures and pulmonary pressures in patients with advanced HF. The absence of adverse events during follow–up suggests that sacubitril/valsartan is safe and well–tolerated in this cohort of patients.
P220 REMOTE MONITORING IN FOLLOW–UP OF ELDERLY PATIENTS WITH HEART FAILURE
Authors: Canestrale R , Mancinelli L
Published: May 2022

Background

Hospitalization is the home route after discharge of elderly patients with heart failure are associated with a high mortality rate (up to 50 % in the first six months) and repeated re–hospitalizations in the first three months, with a peak within thirty days of discharge despite therapy. Telehomecare offers concrete answers to the needs of specialized assistance, usable and in real time, but, on the other hand, the telematic follow–up lends itself to a considerable degree of distrust of non–traditional organizational models.

Objectives

The primary objective of this project is to evaluate the reduction of re–hospitalizations through a telematic follow–up by creating a low–cost virtual clinic. Secondary objective to assess the quality of life in the elderly large patient and the managerial continuity between hospital–home. MATERIALS AND

Methods

An initial narrative review of the literature was conducted by consulting the major data–bases available (Pub–Med, Chinhal and Cochrane Library) and then a qualitative survey of a sample of convenience of 31 users with an average age of 80,4 aa to assess the effectiveness of virtual follow–up . To assess the quality of life (qol) will be administered the questionnaire MLIHF Minnesota living with Heart Failure. The data will then be recorded on an excel sheet and analyzed through the R–Studio software.

Results

Through telemedicine interventions and teleconsultation has been achieved to a greater awareness of the health status of the patient and an empowerment of the selfcare that helps to ensure therapeutic adherence and to contain and/or avoid the progression of NYHA class, also improving the quality of life and the disconfort of travel

Conclusions

Home telemonitoring opens up new perspectives for chronically serious patients and shows potential benefits for patients‘ quality of life and cost containment. In our experience, the monitoring of telemedicine in patients with Heart Failure of high risk age (average age 80.4 years) will lead to an increased awareness of the disease, and the complete and specific training of the caregiver will become fundamental to build a solid social network system for the success of teledisease management.
P221 DAPAGLIFLOZIN ASSOCIATED TO SACUBITRIL/VALSARTAN EXERTS ADDITIVE CARDIOPROTECTION IN HUMAN CARDIOMYOCYTES EXPOSED TO DOXORUBICIN AND TRASTUZUMAB THROUGH MYD88, NLRP3 MEDIATED PATHWAYS AND IMPROVEMENT OF MYTOGENESIS
Authors: Quagliariello V , Iovine M , Buccolo S , Maurea N
Published: May 2022

Introduction

The cumulative incidence of cardiac events in breast cancer patients treated with anthracycline and trastuzumab at 1 year after the diagnosis of cancer was 16.4%, at 2 years 23.8 %, and at 3 years 28.2%. Sodium glucose co–transporter 2 inhibitors showed measurable benefits in reduction of HF hospitalization and cardiovascular mortality. LCZ696 (neprilysin inhibitor + valsartan) as able to lower the risk of cardiovascular events in chronic heart failure.

Purpose

We hypothesize that dapagliflozin associated to LCZ696 could exerts cardioprotective effects in cellular models of doxorubicin and trastuzumab–induced cardiotoxicity

Methods

Human cardiomyocytes (HL–1 cells) were exposed to subclinical concentration of doxorubicin and trastuzumab (100 nM) alone or in combination with dapagliflozin (50 nM) or LCZ696 (at 100 mM) or both in combination for 48h. Cell viability, apoptosis and necrosis were performed. Quantification of MDA– 4–HNE and Ca2+ were performed through spectrophotometric methods. Anti–inflammatory studies were also performed (expression of NLRP3, TLR4/MyD88 pathways, nuclear expression of NF–kB). Intracellular concentration of IL–1α, IL–1β, IL–2, IL–4, IL–6, IL–8, IL–10, IL–12, IL17–α, IL–18, IFN–γ, TNF–α, G–CSF, and GM–CSF were also performed.

Results

Dapagliflozin and LCZ696 increased synergistically the cell viability during exposure to doxorubicin and trastuzumab. Combination of dapagliflozin and LCZ696 reduces Ca2+ overload (–68,4% vs cells treated only to anticancer drugs; p < 0,001) and MDA (mean reduction of 57–63,4 % compared to cells exposed only to anticancer drugs; p < 0,05). The expression of MyD88, NLRP3 and NF–kB were strongly reduced after treatment with dapagliflozin and LCZ–696 (–52,5, –43,7 and –57,3 % vs cells exposed only to anticancer drugs, respectively; p < 0.05). Notably, combination of dapagliflozin and LCZ–696 enhanced the expression of IL–10. Expression of IL–1α, IL–1β, IL–6, IL–8, IL17–α and IL–18 was reduced (p < 0.05). Mitogenesis was strictly improved also as demonstrated by confocal microscope analysis

Conclusion

Dapagliflozin associated to LCZ–696 exerts additive cardioprotective and anti–inflammatory effects compared to each drug alone. Their properties are mediated by the reduction of iCa2+ content that consequently reduces peroxidation and NLRP3– MyD88 expression. These results indicating the potential use of SGLT–2 inhibitors associated to LCZ696 in preclinical models of cardiotoxicity.
P229 IMPROVED CLINICAL–INSTRUMENTAL OUTCOMES IN PATIENTS WITH CHRONIC DILATED HYPERTENSIVE / ISCHEMIC HEART DISEASE, UNDERGOING CCM, CARRIER OF CRTD WITH PERSISTENT SEVERE LEFT VENTRICULAR DYSFUNCTION
Authors: Incampo G , De Luca V , Rizzo D , Bux F , Moramarco M , Valecce R , Robles G , Pirozzi M , Candida T , Marino F , Campagna M , Fiorentino A , Bonfantino M
Published: May 2022

A 62–year–old man repeatedly subjected to PTCA + stent with severe left ventricular dysfunction and estimated FE 15%. After some hospitalizations for heart failure in 2015 he underwent an AICD implant Biventricular. Followed up in our clinics dedicated to heart failure, the patient did not present the characters of the CRT responder presenting a constant high end–systolic volume (224 ml) and none FE improvement of 15%. There was also an asthenia and tendency to inactivity and elevated NT Pro BNP levels despite optimal medical therapy even with entresto 24/26 mg x 2 / day. It has been decided to submit the patient enrolled in the cardiac transplant and / or VAD implantation lists to an implantation procedure of CCM system (cardiac contractility modulation). After two active fixation placement leads on the interventricular septum and connection to the CCM system housed in the subcutaneous pocket right contralateral to the biventricular AICD, the patient was monitored. We have noticed since the first days conditions of hemodynamic stability. Scheduled CCM therapy delivery for 10 hours a day. Following subsequently in the follow up at 3 – 6 – 12 – 18 months the patient showed an improvement of minneshota quality of life questionnaire in heart failure: MLWHFQ (44 at baseline, 17 at two months, 15 to six months, 10 to 12 months and 3 to 18 months), an increase in FE from 15 to 23 up to 26%, a reduction of the NTPROBNP from 13444 to 1178 then climbed back to 5549 and 3712 at 18 months for atrial fibrillation, without any requires re–hospitalization, an increased physical activity of the patient detected by the sensors of the two devices
P233 ASSOCIATIONS BETWEEN LEFT AND RIGHT ATRIAL BIDIMENSIONAL STRAIN AND HEART FAILURE PROGRESSION
Authors: Terazzi E , Diomede N , Correale M , Di Terlizzi V , Barone R , Manuppelli V , Brunetti N , Iacoviello M
Published: May 2022

Background

Two dimensional speckle tracking is an innovative echocardiographic method which analyses myocardial deformation thus allowing the evaluation of both atrial and ventricular function. Recently, new software are available to measure it by semiautomatic analyses.

Aim of the Study

To evaluate the association between left and right atrial Strain and the occurrence of clinical events related to the heart failure (HF) progression. Method. We enrolled 165 outpatients with chronic HF (76% males, NYHA 2.2 ± 0.69, ejection fraction 39±11%). All underwent a clinical and echocardiographic evaluation. An innovative software (TomTec, Philips) was used to analyse the images in order to semi–automatically calculate of atrial Strain. For each patient all the measures relative to the different phases of atrial deformation were considered both for the left atrium (LA) and the right one (RA), i.e. reservoir (r), conduit (cd) and contraction (ct). During the follow–up, we defined the HF progression as hospitalization due to HF worsening and/or heart transplantation and/or cardiovascular death.

Results

During a median follow–up of 5 months, at least one event related to HF progression occurred in 22 patients: all underwent at least one hospitalization, 7 patients died because of cardiovascular reasons and 2 underwent heart transplantation. At Cox univariate analysis, LASr (HR: 0,93; 95%CI: 0,88–0,97, p: 0.004; C–index 0,7), LAScd (HR: 1,09; 95%CI: 1,01–1,19; p: 0,023; C–index: 0,64), RASr (HR: 0,95; 95%CI: 0,90–0,99; p: 0,031; C–index: 0,68), RAScd (HR: 1,08; 95%CI: 1,01–1,15; p: 0,021; C–index: 0,67), but not LASct (HR: 1,04; 95%CI: 0,99–1,09; p 0,094; C–index 0,62) and RASct (HR: 1,02; 95%CI: 0,96–1,09; p: 0,61; C–index: 0,55), were significantly associated to HF progression. LASr and RASr showed the higher accuracy in predicting the events by the estimation of C index. At ROC curve analysis, for LASr the best cut–off was 16.1% (Sensitivity 83%, Specificity 56%) and for RASr 17.3% (Sensitivity 79%, Specificity 60%). Figure shows Kaplan–Meier curves for the considered end–point according with these cut–offs.

Conclusions

The preliminary results of this study have showed the association between LA and RA Strain variables and the HF progression. The prosecution of this study will be finalised to demonstrate the prognostic independent and incremental significance.
P234 A RARE CASE OF ACUTE RIGHT HEART FAILURE PRESENTED IN A CASE REPORT
Authors: Avondo S , Zaccaro L , Albani S , Pelloni E , Bonino C , Biava L , Scacciatella P
Published: May 2022

Case Summary

A 62–year–old male with multiple cardiovascular risk factors, presented at the ED with signs and symptoms of right heart failure, Doppler echocardiography showed a severe dilatation and dysfunction of the right ventricle and left ventricular diastolic dysfunction. After initial stabilization with diuretics and inotropes, the patient performed a coronary angiogram with evidence of severe multivessel coronary artery disease and combined pre–capillary and post–capillary pulmonary hypertension as shown by the right heart catheterization. After complete revascularization, the diastolic function of the left ventricle improved dramatically, and the right ventricle recovered completely.

Discussion

We presented a paradigmatical case of acute right heart failure secondary to left ventricular diastolic impairment in a patient affected by severe ischemic coronary artery disease. Several risk factors are associated with RVD in HFpEF: atrial fibrillation, male sex, chronic obstructive pulmonary disease. Diastolic performance of the LV is one of the main determinants of the right ventricular function, which, in turn, is proven to have prognostic implication in HFpEF. Nowadays, there is no evidence–based treatment for right heart failure secondary to decompensated HFpEF and therapy should be tailored to the individual patient’s response.
P238 CARDIAC CONTRACTILITY MODULATION THERAPY: INITIAL MONOCENTRIC EXPERIENCE
Authors: D‘Alleva A , Sacchetta D , Magnano R , Forlani D , Di Marco M , Pezzi L , Vitulli P , Fulgenzi F , Verrengia E , Paloscia L
Published: May 2022

Cardiac contractility modulation therapy consists in the delivery, by a device implanted in the patient at the level of the subclavicular region and connected to the heart through leads that send high intensity electrical impulses within the absolute refractory period of the potential of myocardial action. These pulses are delivered in cycles of 1 hour 7 times a day, each interspersed with pauses of 2–3 hours. CCM has been shown to be able to improve myocardial contractility through better management of intracellular calcium by the cardiomyocyte, exerting short and long–term effects, even managing to induce a positive remodulation of the gene expression of cardiac cells. The recent ESC 2021 guidelines indicate that cardiac contractility modulation therapy (CCM) was evaluated in patients with heart failure, FE 25%–45% and normal QRS duration (<130 ms) considering pVO2, QoL, 6MWT. The modulation of cardiac contractility improves symptoms and exercise tolerance and reduces re–hospitalization for heart failure (HF).

The purpose of this work is to show our little experience on the use of CCM in patients suffering from heart failure.

Materials and methods

4 male patients, aged 38–75 years, with heart failure, on optimal medical therapy, NYHA class III – IV, QRS <130 msec, FE 25–45%, hospitalized for implantation by CCM. NYHA, FE and BNP rated. The device was implanted in 4 patients without significant complications.

Results

In the 3 and 6 month follow–up, patients reported an improvement in symptoms, better exercise capacity and consequently a transition to a lower NYHA class (II – III). BNP values were lower than baseline. Upon checking the defibrillator, the trend of fluid accumulation using the optivol algorithm did not show significant levels of accumulation. No further hospitalizations for heart failure exacerbation.

Conclusion

The data limited to our little experience show how CCM produces similar results to those demonstrated in previous studies in subjects with 25% ≤LVEF≤45% and QRS <130 ms; CCM therapy improves clinical outcomes in terms of exercise tolerance and quality of life, long–term survival and reduces hospitalizations.
P243 RELEVANCE OF RENAL RESISTANCE INDEX INCREASE AFTER CORONARY ANGIOGRAPHY
Authors: Barone R , Goffredo G , Di Terlizzi V , Correale M , Casavecchia G , Ieva R , Cuculo A , Brunetti N , Iacoviello M
Published: May 2022

Background

Renal resistance index is a Doppler derived measure which is able to reflect the pathophysiological background of Cardiorenal Syndrome (CS). There are no data about the influence of the intravascular administration of contrast media on RRI and its relationship with worsening of renal function (WRF).

Aim of the Study

To evaluate changes in renal resistance index (RRI) after coronary angiography in patients with and without WRF. METHODS We enrolled 115 patients (mean age 64 years, 73% males, 84% hypertensive, 43% diabetic, 30% with acute coronary syndrome, 21% affected by chronic heart failure, CHF, with a mean left ventricular ejection fraction, LVEF, of 51±11) with suspected coronary artery disease, stable angina, or acute coronary syndromes who have been referred for coronary angiography (with or without pre–existing renal impairment). Renal arterial echo–color Doppler was used to calculate RRI before and 48 hours after coronary angiography. WRF was defined as an increase of creatinine >0.3 mg/dl and of at least 25% from baseline 24–48 hours after coronary angiography.

Results

Fourteen (12%) among the enrolled patients showed WRF. As expected, a significant increase of creatinine serum levels was observed in patients with WRF (from 1.14±0.40 to 1.71±0.49, p < 0.001) but not those without (from 0.89±0.27 to 0.92±0.28, p n.s.) WRF. On the other hand, RRI significantly increased both in patients with (from 72.8±4.3 to 76.4±5.2, p < 0.05) and without (from 63.1±7.2 to 65.4±7.1, p < 0.05). However, both at baseline and after angiography, patients with WRF showed RRI values significantly greater when compared with those without. At ROC curve analyses for WRF, the baseline and after angiography RRI sowed similar AUC (0.88 and 0.90, respectively) and for both RRI values the best cut–off was 70% (sensitivity of 79% and 93% and Specificity of 93% and 82%, respectively). As shown in the figure, the high predictive accuracy of RRI values was due to the fact that, although increased after angiography, the proportion of patients without WRF and with RRI>70% remained very low.

Conclusion

After coronary angiography RRI significantly increase both in patients with and without WRF. However, a larger proportion of patients with WRF present a critically increased RRI, i.e. equal or above 70%, before and after angiography probably because reflecting the pathophysiological background underlying the progression of cardiorenal syndrome.